Alvotech's 427% revenue surge in 2024—fueled by its biosimilar portfolio and global expansion—highlights the booming ...

Learn more about whether Alvotech or Vericel Corporation is a better investment based on AAII's A+ Investor grades, which ...

It's been a mediocre week for Alvotech ( NASDAQ:ALVO ) shareholders, with the stock dropping 17% to US$9.55 in the ...

Learn more about whether Alvotech or Grifols, S.A. is a better investment based on AAII's A+ Investor grades, which compare ...

Northland Securities analyst Carl Byrnes maintained a Buy rating on Alvotech (ALVO – Research Report) today and set a price target of $28.00.

REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025, at 8:00 am ET (12:00pm ...

Alvotech acquires Xbrane's R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities ...

Alvotech (NASDAQ:ALVOW – Get Free Report) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 6,000 shares, a decline of 36.2% from ...

Revenue: US$492.0m (up 427% from FY 2023). Net loss: US$231.9m (loss narrowed by 58% from FY 2023). US$0.87 loss per share (improved from US$2.43 loss in FY 2023). Revenue exceeded analyst ...

Alvotech, a biotech firm focused on biosimilar medicine development, announced the acquisition of Xbrane Biopharma’s R&D operations and a biosimilar candidate named XB003, aimed at extending its ...

All applications have been subsequently accepted by the relevant regulatory authorities. Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025 ...